A New Perspective for Chinese Medicine Intervention for Coronary Artery Disease: Targeting Inflammation

Overview

Journal Chin J Integr Med

Date 2018 Aug 23

PMID 30132247

Citations 3

Authors

Si-Ming Li

Jin-Gen Li

Hao Xu

Affiliations

Soon will be listed here.

Abstract

Inflammation, which plays a critical role in atherosclerosis and the occurrence of acute cardiovascular events, may be a new target for treatment of coronary artery disease (CAD) to reduce residual cardiovascular risk. Recently, Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS), the largest scale clinical trial that targeted inflammation but not lipids, has affirmed for the first time the inflammatory hypothesis of artherosclerosis and marked the advent of an exciting era of targeting inflammation for the prevention and treatment of cardiovascular diseases. Chinese medicine (CM) is a promising adjuvant therapy for CAD in light of its safety and pleiotropic effect of anti-inflammation, anti-platelet, lipid-regulating, endothelium-protection, microcirculation-improving, etc. In recent years, exploration of anti-inflammatory treatment of CAD with CM has been going on from theory to practice. Taking CANTOS as an example, the design strategy to combine CM and Western medicine to inhibit inflammation were discussed in this paper, which might provide a new perspective for CM intervention on CAD.

Citing Articles

Intervention Effect of Traditional Chinese Medicine Hot Pressing Combined with Health Education on the Adolescent's Visual Fatigue.

Tang Y, Wei X, Huang Y, Huang J, Jin W, Lu Y J Healthc Eng. 2022; 2022:2450197.

PMID: 35360485 PMC: 8964189. DOI: 10.1155/2022/2450197.

Therapeutic Effects of Traditional Chinese Medicine on Cardiovascular Diseases: the Central Role of Calcium Signaling.

Li Y, Zhang Z, Li S, Yu T, Jia Z Front Pharmacol. 2021; 12:682273.

PMID: 34305595 PMC: 8299363. DOI: 10.3389/fphar.2021.682273.

Taoren Honghua Drug Attenuates Atherosclerosis and Plays an Anti-Inflammatory Role in ApoE Knock-Out Mice and RAW264.7 Cells.

Wang Y, Jia Q, Zhang Y, Wei J, Liu P Front Pharmacol. 2020; 11:1070.

PMID: 32765273 PMC: 7379336. DOI: 10.3389/fphar.2020.01070.

References

Ridker P, Rifai N, Rose L, Buring J, Cook N . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20):1557-65. DOI: 10.1056/NEJMoa021993. View

Ridker P . Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3):363-9. DOI: 10.1161/01.cir.0000053730.47739.3c. View

Ridker P . Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003; 108(19):2292-7. DOI: 10.1161/01.CIR.0000100688.17280.E6. View

Li J, Fang C . Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses. 2004; 63(1):100-2. DOI: 10.1016/j.mehy.2004.01.029. View

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

Ridker P, Cannon C, Morrow D, Rifai N, Rose L, McCabe C . C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352(1):20-8. DOI: 10.1056/NEJMoa042378. View

Nissen S, Tuzcu E, Schoenhagen P, Crowe T, Sasiela W, Tsai J . Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352(1):29-38. DOI: 10.1056/NEJMoa042000. View

Hansson G . Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16):1685-95. DOI: 10.1056/NEJMra043430. View

Wen C, Xu H, Huang Q . [Effect of drugs for promoting blood circulation on blood lipids and inflammatory reaction of atherosclerotic plaques in ApoE gene deficiency mice]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005; 25(4):345-9. View

10.

Li J, Li Y, Fang C, Hui R, Yang Y, Cheng J . Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. Heart. 2005; 92(4):529-30. PMC: 1860880. DOI: 10.1136/hrt.2004.057489. View

11.

Zhou M, Xu H, Chen K . [Effects of some active ingredients of Chinese drugs for activating blood circulation and detoxicating on blood lipids and atherosclerotic plaque inflammatory reaction in ApoE-gene knockout mice]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008; 28(2):126-30. View

12.

Musunuru K, Kral B, Blumenthal R, Fuster V, Campbell C, Gluckman T . The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008; 5(10):621-35. PMC: 2639398. DOI: 10.1038/ncpcardio1322. View

13.

Koenig W, Khuseyinova N . Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2008; 23(1):85-92. DOI: 10.1007/s10557-008-6135-6. View

14.

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

15.

Buckley D, Fu R, Freeman M, Rogers K, Helfand M . C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151(7):483-95. DOI: 10.7326/0003-4819-151-7-200910060-00009. View

16.

Libby P, Ridker P, Hansson G . Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54(23):2129-38. PMC: 2834169. DOI: 10.1016/j.jacc.2009.09.009. View

17.

Kaptoge S, Di Angelantonio E, Lowe G, Pepys M, Thompson S, Collins R . C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2009; 375(9709):132-40. PMC: 3162187. DOI: 10.1016/S0140-6736(09)61717-7. View

18.

Chen K, Shi D, Xu H . [The criterion of syndrome differentiation and quantification for stable coronary heart disease caused by etiological toxin of Chinese medicine]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011; 31(3):313-4. View

19.

Libby P, Ridker P, Hansson G . Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473(7347):317-25. DOI: 10.1038/nature10146. View

20.

Huang Y, Yin H, Ma X, Wang J, Liu Q, Wu C . Correlation between Fc γ R III a and aortic atherosclerotic plaque destabilization in ApoE knockout mice and intervention effects of effective components of chuanxiong rhizome and red peony root. Chin J Integr Med. 2011; 17(5):355-60. DOI: 10.1007/s11655-011-0726-y. View